Vitality Watch

Dossier pubmed review 09-sep-2026
Narrative review or expert overview without new data

Canonical complement C3a-C3AR1 signalling in ageing and age-related disease: Cellular mechanisms, tissue-specific effects and translational challenges.

Key claim: Chronic C3a–C3AR1 signalling is an ageing-sensitive axis that reprograms macrophages and microglia, drives immunometabolic and endothelial dysfunction, and amplifies inflammageing, with the strongest chronological-ageing support in visceral adipose tissue and the neurovascular unit, while systemic inhibition faces context-dependent safety trade-offs.

Abstract

As the body ages, chronic low-grade inflammation, metabolic dysregulation, and loss of tissue resilience occur; however, the pathways linking these processes have not been fully characterized. Beyond traditional host defence, the canonical complement C3a-C3AR1 signalling axis has been identified as an ageing-sensitive pathway. Studies involving naturally aged animals, older human cohorts, and models of age-related diseases indicate that chronic C3a-C3AR1 signalling can drive the reprogramming of macrophages and microglia, influence immunometabolic processes, cause endothelial dysfunction, and amplify inflammatory responses. Chronological ageing provides the strongest mechanistic support for complement involvement across the visceral adipose tissue and neurovascular unit, including altered complement signalling and inflammageing, blood-brain barrier disruption, microglial state transitions, and cognitive impairment. There are additional studies on the tissue-specific involvement of this pathway in retinal, skeletal, cardiovascular, and renal diseases, although many of these studies have been conducted in models of injury or disease rather than chronological ageing. The context dependency of C3a-C3AR1 signalling also means that systemic inhibition may be complicated by the roles of C3a and C3AR1 in antimicrobial defense, phagocytosis, debris clearance, and tissue repair. C3a is a candidate biomarker of inflammatory and biological ageing; however, it is currently limited by insufficient specificity and preanalytical stability and needs to be validated longitudinally before being applied in clinical practice. Herein, we critically review the age-dependent regulation of canonical complement C3a-C3AR1 signalling, its cell- and tissue-specific effects, and the evidence linking this axis to ageing and age-related diseases.

Why this matters

Complement has been discussed in this area mainly through the intracellular complosome frame; this synthesis pulls the canonical extracellular C3a–C3AR1 axis into the aging picture as a tissue-context node tying inflammaging, immunometabolism, and neurovascular decline together, with visceral adipose tissue and the neurovascular unit carrying the strongest chronological-aging signal. It also flags that systemic C3AR1 blockade — an obvious drug-target pitch — collides with context-dependent safety trade-offs, so the biology is not cleanly a therapeutic story yet. This is a review-level consolidation, not new causal evidence, and the human-translation gap remains open.

Source

Link

Briefing card

Canonical complement C3a-C3AR1 signalling in ageing and age-related disease: Cellular mechanisms, tissue-specific effects and translational challenges.
Stage: review · pubmed · 09-sep-2026

If you follow complement-targeting anti-aging drug narratives, this review argues the strongest ageing signal sits in adipose tissue and brain vasculature but warns systemic C3AR1 inhibition carries context-dependent safety trade-offs.

Chronic C3a–C3AR1 signalling is an ageing-sensitive axis that reprograms macrophages and microglia, drives immunometabolic and endothelial dysfunction, and amplifies inflammageing, with the strongest chronological-ageing support in visceral adipose tissue and the neurovascular unit, while systemic inhibition faces context-dependent safety trade-offs.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.arr.2026.103367

build build 880 · 2bcef25 · 2026-11-18